Brian joined LabCorp in September 2017 to serve as Chief Medical Officer for the enterprise. As CMO, he helps drive our company’s clinical strategies around health policy and regulatory efforts, value-based care models and clinical standards of care in our changing health care payment landscape. Prior to joining LabCorp, Brian served a variety of roles at Blue Cross & Blue Shield of North Carolina, including Chief Medical Officer. He was responsible for healthcare program strategy, care management, network provider contracting, medical coverage policy, medical expense initiatives, care quality and pharmacy. Read his full bio.

Interview with Brian Caveney of LabCorp

Q: What need is LabCorp addressing?

A: The timeless issues LabCorp continues to address are those related to delivering world-class diagnostics solutions, bringing innovative medicines to patients faster and using technology to improve the delivery of healthcare. Our innovations help to shorten clinical trial times and expand therapeutic options and diagnostics for doctors, positively affecting quality and cost.

Q: What are the products and/or services LabCorp offers/develops to address this need? What makes LabCorp unique?

A: LabCorp understands that one size does not always fit all, as the future of healthcare is personal. By bringing together world-class diagnostics through LabCorp Diagnostics and end-to-end drug development capabilities through Covance Drug Development, LabCorp is uniquely positioned at the intersection of research and patient care to enable more precise and individualized healthcare.

Q: What is your role at LabCorp and what excites you about your work?

A: Every day, I am amazed and impressed by the high level of scientific talent that we have across LabCorp Diagnostics and Covance Drug Development; the level of commitment that employees have to our mission of improving health and improving lives; and our ability to deliver world-class solutions to doctors and patients navigating the increasingly complex healthcare system.

Much of my focus is on our three strategic initiatives: value-based care, consumer engagement and streamlining drug development. LabCorp has chosen to focus on these initiatives because they are the areas where we can bring the most value. More specifically, we are addressing the empowerment of consumers in managing their own healthcare, and exploring how we can use diagnostics to improve healthcare decision-making and control costs. Another area where we can make a big difference is in helping our clients bring medicines to market faster by addressing the time and complexity of clinical trials and patient recruitment.

Q: When thinking about LabCorp and the domain LabCorp is working in, what are some of the recent breakthroughs that are propelling the field forward and how will they impact healthcare?

A: LabCorp’s broad portfolio of tests includes many options — from companion diagnostics and pharmacogenetics to genomics and therapeutic drug monitoring — that can help providers identify the right drug, at the right dose, for the right patient.

The majority of drug therapies in development today are driven by biomarkers, or laboratory assays that can indicate whether patients have a particular condition or disease state. These biomarker-driven efforts are what can lead to the development of the appropriate companion diagnostic assays, or in certain situations, a complementary diagnostic. LabCorp is the market leader for the development, validation, and commercialization of companion diagnostics, which are key drivers of personalized medicine.

Additionally, biologics are the fastest-growing drug class and make up more than one-third of the pharmaceutical pipeline. Biologic drugs—which are used to treat many different diseases and conditions, such as Crohn’s disease, rheumatoid arthritis and multiple sclerosis—can not only be expensive, but also highly variable in effectiveness from patient to patient. Therapeutic drug monitoring (TDM) is an area of growth in precision medicine due to increased demand for better treatment outcomes and minimum side effects. TDM is known to promote better patient outcomes and cost savings for payers. One study found a cost savings of 28 to 34 percent through the use of some TDM tests. LabCorp offers the most comprehensive offerings of TDM tests available for many of the highest-grossing prescription drugs on the market.

Q: What are the short-term challenges that LabCorp and its peers are facing?

A: As always, there are a myriad of trends and challenges on the horizon, particularly as our industry experiences rapid changes. As healthcare regulatory and payment systems transform, and the industry experiences cuts to government funding, we continue to innovate our business to address needs for the customer segments we serve across the healthcare continuum, from consumers and physicians to managed care partners and biopharmaceutical companies.

Q: Is there anything else you would like to share with the PMWC audience?

A: Collectively, we need to continue building a solid evidence base for the appropriate use of advanced diagnostics that can help improve clinical outcomes, reduce medication errors, and impact the total cost of care. If we can demonstrate those attributes, precision medicine will flourish in the future.

Interview with Andrew Carroll of Google AI

Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are your thoughts?

A: I believe that applying AI technologies in healthcare will make physicians more valuable, and will make their careers more enjoyable and sustainable.

Read More

Interview with L. Staton Noel III of Panaceutics

Q: What need is Panaceutics addressing?

A: One of the key barriers to making precision/personalized wellness and healthcare products is the contradictory goal of manufacturing individualized products on a large scale. Meeting demand for personalized products can be expensive and logistically challenging.

Read More

Interview with Joe Zhang of Burning Rock Dx

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend?

A: The milestones in my mind include the first FDA clearance of Next Gen Sequencing instrument, MiSeqDx in 2013, this opened a new door for clinical utilization of parallel gene alteration detection in clinical setting.

Read More

Why are Scientists So Upset About The First CRISPR Babies?

The use of new technologies can provide breakthrough benefits for both patients and providers. However, with increased sharing comes increased risks to the security and privacy of patient data. Currently data is being accumulated across many organizations and initiatives but is often either siloed or simply not accessible. Researchers suggest that patient education tactics can help quell security concerns during patient data sharing.

Read More

Interview with Kara Davis of Stanford

Q: The Nobel Price in Medicine was awarded recently to James Allison and Tasuku for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” What is your first-hand experience the impact that those new drugs had on patients?

A: These immune checkpoint inhibitors have been an incredible demonstration of the ability of the immune system to control and in some cases.

Read More

Interview with Shannon J. McCall of Duke University

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend?

A: After several years of the promise of precision medicine and abundant clinical trial work, the recent FDA approval of solid-tumor-agnostic therapies dependent on molecular biomarkers has catapulted genomic/precision medicine into the standard-of-care for late stage cancer.

Read More

Interview with Tao Chen of Paragon Genomics, Inc.

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling for clinical Dx. How soon, do you think, will we see accelerated growth and what can we expect?

A: For whole genome sequencing to be a reliable clinical tool, it will largely depend on the cost of sequencing the genome and our ability to interpret the data.

Read More

Call for Action: The Time is Now for Patient Data Interoperability

The use of new technologies can provide breakthrough benefits for both patients and providers. However, with increased sharing comes increased risks to the security and privacy of patient data. Currently data is being accumulated across many organizations and initiatives but is often either siloed or simply not accessible. Researchers suggest that patient education tactics can help quell security concerns during patient data sharing.

Read More

Interview with Andrew Magis of Arivale

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling. How soon, do you think, will we see what kind of accelerated growth?

A: I think the acceleration has already begun. Large sequencing projects such as NHLBI Trans-omics for Precision Medicine (TOPMed) and NIH All of Us are sequencing 150,000 and 1 million individuals, respectively.

Read More

Interview with Emily Leproust of Twist Bioscience

Q: NGS is enhancing patient care through improved diagnostic sensitivity and more precise therapeutic targeting. Prominent examples include cystic fibrosis and cancer. What other clinical areas NGS will most likely to change the standard-of-care in the near future?

A: Preventative medicine – using genetic data to identify traits that have the potential to cause harm in the future.

Read More

Interview with Michael Phelps of UCLA

Q: You invented the PET scanner that changed the lives of millions of patients with cancer, brain and heart diseases. What are the potential benefits to patients of combining PET with radio-ablation technologies?

A: PET provides imaging assays of the biology of disease in many diseases today.

Read More

Interview with Daniela Ushizima of Lawrence Berkeley National Lab

Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are your thoughts?

A: I really hope that human physicians will not be replaced by machines in the foreseeable future.

Read More

Interview with Amy Compton-Phillips of Providence St. Joseph Health

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend? What technological advancements are driving this change?

A: Genomic medicine is poised to move quickly from the research realm into integration with healthcare delivery, but there is always a time lapse between technology advances and what we do with those advances.

Read More

Interview with James Taylor of Precision NanoSystems

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: Patients are already receiving treatment using novel gene and cell therapies.

Read More

Interview with Julie Eggington of Center for Genomic Interpretation

Q: Together with Robert Burton you founded the Center for Genomic Interpretation (CGI), a non-profit organization. Can you tell us more about CGI and the mission behind it?

A: CGI’s mission is to drive quality in clinical genetics and genomics. CGI works primarily with laboratories, health insurance payers, clinicians, and patients/consumers.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 16th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 20-23, 2019. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!